TEVETEN TABLETS 300 MG

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

EPROSARTAN (EPROSARTAN MESYLATE)

Доступна з:

SOLVAY PHARMA INC

Код атс:

C09CA02

ІПН (Міжнародна Ім'я):

EPROSARTAN

Дозування:

300MG

Фармацевтична форма:

TABLET

Склад:

EPROSARTAN (EPROSARTAN MESYLATE) 300MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

60

Тип рецепту:

Prescription

Терапевтична области:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Огляд продуктів:

Active ingredient group (AIG) number: 0137701001; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

1999-08-19

Характеристики продукта

_ _
_Appendix E - Product Monograph Template – Standard (DRAFT) –
March 29, 2005 _
_Page 1 of 35_
PRODUCT MONOGRAPH
Pr
TEVETEN
®
Eprosartan Mesylate Tablets
(containing 400 mg and 600 mg eprosartan)
Angiotensin II receptor (AT
1
) antagonist
Date of Preparation:
August 20, 1999
Date of Revision:
May 25, 2006
Submission Control No: 099001
_ _
_Appendix E - Product Monograph Template – Standard (DRAFT) –
March 29, 2005 _
_Page 2 of 35_
Table of Contents
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL
USE..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND
PRECAUTIONS..................................................................................4
ADVERSE
REACTIONS....................................................................................................6
DRUG INTERACTIONS
..................................................................................................11
DOSAGE AND
ADMINISTRATION..............................................................................12
OVERDOSAGE
................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
............................................................14
STORAGE AND
STABILITY..........................................................................................17
SPECIAL HANDLING INSTRUCTIONS
.......................................................................17
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................17
PART II: SCIENTIFIC INFORMATION
...............................................................................19
PHARMACEUTICAL
INFORMATION....................................